-
Nature Immunology: Weiping Zou's team from the University of Michigan reveals a new mechanism of MDM2-p53 inhibitor tumor immunology
Time of Update: 2021-04-13
On March 26, the internationally renowned journal "Nature Immunology" published an online article "The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity" by Dr.
"This study clarified the new mechanism of tumor immunology mediated by T cells by the MDM2-STAT5 signal axis in detail.
-
JCO: HER2 expression in metastatic gastric cancer and its impact on survival
Time of Update: 2021-04-13
Trastuzumab is the only targeted drug approved for the treatment of human epidermal growth factor receptor 2 positive (HER2+) metastatic gastric cancer (mGC).
-
BMJ Sub-Journal: The data of more than 1.9 million people in 168 countries confirm that the benefits of exercise far exceed expectations!
Time of Update: 2021-04-13
9 million people in 168 countries, and assessed premature deaths and all-cause mortality caused by lack of exercise, cardiovascular disease mortality, and non-communicable diseases (including coronaryThe incidence ofheart disease, stroke, hypertension, type 2 diabetes , dementia, depression, and various cancers).
-
JAMA Sub-Journal: The data of 6.3 million people tell you that obesity is not harmful to health without benefiting all!
Time of Update: 2021-04-13
In particular, a meta-analysis of 230 cohort studies including more than 30 million people found that both obesity and overweight are associated with an increased risk of death from all causes.
-
Nat Commun: Multi-task deep learning method to predict the treatment response of patients with solid tumors
Time of Update: 2021-04-13
The method of capturing dynamic information in the longitudinal image can be widely used in the screening of solid tumor patients , the evaluation of treatment response, and the monitoring of diseases.
-
Uterine fibroids, Relugolix treatment of uterine fibroids shows potential long-term benefits
Time of Update: 2021-04-13
Pfizer and Myovant Sciences announced that Relugolix combination therapy may have "potential benefits" for the long-term treatment of patients with uterine fibroids.
Juan Camilo Arjona Ferreira, Chief Medical Officer of Myovant Sciences, said: "We are very pleased to see the positive data from the LIBERTY study, which supports the potential benefits of long-term Relugolix combination therapy.
-
Int J Radiat Oncol Biol Phys: Failure to follow the guidelines in radiotherapy will reduce the survival rate of patients with locally advanced pancreatic cancer!
Time of Update: 2021-04-13
Pancreatic cancerThe main results of the LAP07 multicenter randomized study (international randomized phase 3 trial) showed that in patients with locally advanced pancreatic cancer that were controlled 4 months after induction chemotherapy, there was no significant difference in the overall survival rate of patients with chemotherapy and continuous chemotherapy .
-
Tecentriq first-line treatment of metastatic non-small cell lung cancer, CHMP holds positive opinions
Time of Update: 2021-04-13
Roche announced today that the European Medicines Management Agency (EMA) Committee for Medicinal human use (CHMP) has recommended approval of the Tecentriq® (atezolizumab) as a high expression of PD-L1 and no epidermal growth factor receptor (EGFR) or anaplastic lymphoma First-line therapy for metastatic non-small cell lung cancer ( NSCLC ) with abnormal genomic tumors of ALK .
-
Recalling the cloud: uniQure announces that gene therapy for hemophilia is "very unlikely" to cause lung cancer and will resume clinical trials
Time of Update: 2021-04-13
S. Food and Drug Administration (FDA) review, uniQure announced that its hemophilia B gene therapy Etranacogene dezaparvovec (AMT-061) is "very unlikely (Highly unlikely)” led to liver cancer in patients .
-
Lancet oncol: Phase 3 randomized trial | Second-line FOLFOX chemotherapy can significantly improve the prognosis of advanced cholangiocarcinoma
Time of Update: 2021-04-13
The prognosis of advanced cholangiocarcinoma is poor. Cisplatin and gemcitabine are standard first-line chemotherapy, but there is no reliable evidence to support second-line chemotherapy. This stud
-
"2021 Oncology Field Standardized Diagnosis and Treatment Training and Inter-hospital Exchange" project launched
Time of Update: 2021-04-13
On March 28, the "Healthy China 2030"-Oncology Health Plan's "2021 Oncology Field Standardized Diagnosis and Treatment Training and Inter-hospital Exchange" project sponsored by the National Health Co
-
GenScript Biotechnology released its 2020 annual results, the non-cellular therapy business achieved the fastest growth rate in 5 years, and the net profit increased by more than 100%
Time of Update: 2021-04-13
9% to US$315 million, the fastest growth rate in the past 5 years; Legend Bio, a subsidiary of the cell therapy business , successfully landed on Nasda in June 2020 as the first share of CAR-T in China Gram, its class 1 new therapeutic biological product, cilta-cel, received China’s first breakthrough therapy certification in August 2020, and formally reported it to the U.
-
20% of nasopharyngeal cancer patients face recurrence and metastasis, immunotherapy may become a new "life-saving" method
Time of Update: 2021-03-30
Professor Hu Chaosu said that with the popularization of intensity-modulated radiotherapy and the application of comprehensive treatment, chemotherapy and the comprehensive application of targeted drugs, the five-year survival rate of nasopharyngeal cancer patients is as high as 80 % Above, compared with other malignant tumors, the curative effect is amazing.
-
JCO: Tipifarnib is effective for recurrent and/or metastatic head and neck squamous cell carcinoma
Time of Update: 2021-03-30
The results showed that Tipifarnib has a significant effect on R/M mHRAS-HNSCC patients with HRAS mutations.
Although targeted therapy has recently been included in standard treatment, the prognosis of R/M HNSCC patients is still very poor, with an estimated median overall survival of 13-15 months.
-
Br J Cancer: PI3K signaling pathway activation leads to eribulin resistance in HER2-negative breast cancer
Time of Update: 2021-03-30
Researchers evaluated the drug resistance of eribulin in the HER2-BC cell line and patient-derived xenografts, and studied its correlation with mutations in the PI3K/AKT signaling pathway.
-
Gut: Can anti-hepatitis C virus treatment prevent liver cancer recurrence after liver cancer treatment?
Time of Update: 2021-03-30
Assess the risk of liver cancer recurrence in these patients after taking DAAData from 977 patients from 21 HCV-related cirrhosis and HCC studies were included.
The recurrence rate and death risk of patients in the DAA group were 20/100 person-years (95%CI 13.
-
Revealing cancer mutations may be expected to help develop new cancer detection technologies and individualized anti-cancer therapies
Time of Update: 2021-03-30
March 26, 2021 // - Recently, in a research report titled "The landscape of the heritable cancer genome" published in the international journal Cancer Research , scientists from the University of Edinburgh and other institutions said through research that, Revealing new cancer mutations may be expected to help enhance the diagnosis of cancer and the development of personalized anti-cancer therapies.
-
Nat Commun: The clonal structure of malignant pleural mesothelioma can be used as a prognostic indicator and affect the tumor microenvironment
Time of Update: 2021-03-30
The results of this study reveal the potential evolutionary bottleneck of druggable drugs in MPM, as well as the influence of clonal structure on the shaping of the immune pattern, and may determine the clinical response to immune checkpoint suppression.
-
The latest advances in clinical research on the first-line treatment of advanced hepatocellular carcinoma with "Treprizumab + Bevacizumab" are released
Time of Update: 2021-03-30
Take Junshi Bio’s teriprizumab as an example, in the combination of teriprizumab and bevacizumab we released today In the Phase II clinical trial for the first-line treatment of advanced hepatocellular carcinoma, we are pleased to see very exciting data results, which show that innovative drugs with China’s independent intellectual property rights can bring international-level treatment options for liver cancer patients.
-
Br J Cancer: The prognostic value of preoperative systemic inflammatory response (SIR) measurement in colon cancer patients
Time of Update: 2021-03-30
In summary, the results of the study show that for patients with colon cancer undergoing radical surgery, the SIG score combined with mGPS and NLR before surgery can better determine the patient's SIR response.
